Hypercholesterolemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000
Buy Report Download FREE Resources

Published: October 31, 2022 Report Code: GDGMDHC22364IDB-ST

Select Item

Hypercholesterolemia Pipeline Drugs Market Overview

The Hypercholesterolemia pipeline drugs market research report provides comprehensive information on the therapeutics under development for Hypercholesterolemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report reviews key players involved in therapeutic development for Hypercholesterolemia and features dormant and discontinued projects.

Hypercholesterolemia Pipeline Drugs Market Segmentation by Targets

Some of the key targets of the Hypercholesterolemia pipeline drugs market are Proprotein Convertase Subtilisin/Kexin Type 9, 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase, Angiopoietin Related Protein 3, Apolipoprotein C III, Niemann Pick C1 Like Protein 1, Low Density Lipoprotein Receptor, Angiopoietin Related Protein 4, ATP Citrate Synthase (ATP Citrate, Cholesteryl Ester Transfer Protein, and Squalene Synthase.

Hypercholesterolemia Pipeline Drugs Market Analysis, by Targets

Hypercholesterolemia Pipeline Drugs Market Analysis, by Targets

For more Hypercholesterolemia pipeline drugs market target insights, download a free report sample

Hypercholesterolemia Pipeline Drugs Market Segmentation by Mechanisms of Action

Some of the key mechanisms of action of the Hypercholesterolemia pipeline drugs market are Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor, 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase Inhibitor, Angiopoietin Related Protein 3 Inhibitor, Apolipoprotein C III Inhibitor, Niemann Pick C1 Like Protein 1 Inhibitor, Low Density Lipoprotein Receptor Agonist, Angiopoietin Related Protein 4 Inhibitor, ATP Citrate Synthase (ATP Citrate Inhibitor, Cholesteryl Ester Transfer Protein Inhibitor, and Squalene Synthase Inhibitor.

Hypercholesterolemia Pipeline Drugs Market Analysis, by Mechanisms of Action

Hypercholesterolemia Pipeline Drugs Market Analysis, by Mechanisms of Action

For more mechanism of action insights into the Hypercholesterolemia pipeline drugs market, download a free report sample

Hypercholesterolemia Pipeline Drugs Market Segmentation by Routes of Administration

Some of the key routes of administration in the Hypercholesterolemia pipeline drugs market are oral, subcutaneous, intravenous, buccal, intramuscular, intraperitoneal, nasal, sublingual, topical, and transdermal.

Hypercholesterolemia Pipeline Drugs Market Analysis, by Routes of Administration

Hypercholesterolemia Pipeline Drugs Market Analysis, by Routes of Administration

For more routes of administration insights into the Hypercholesterolemia pipeline drugs market, download a free report sample

Hypercholesterolemia Pipeline Drugs Market Segmentation by Molecule Types

The key molecule types in the Hypercholesterolemia pipeline drugs market are small molecule, monoclonal antibody, gene therapy, antisense oligonucleotide, antisense RNAi oligonucleotide, synthetic peptide, peptide, biologic, conjugate vaccine, fusion protein, polymer, and subunit vaccine.

Hypercholesterolemia Pipeline Drugs Market Analysis, by Molecule Types

Hypercholesterolemia Pipeline Drugs Market Analysis, by Molecule Types

For more molecule type insights into the Hypercholesterolemia pipeline drugs market, download a free report sample

Hypercholesterolemia Pipeline Drugs Market - Competitive Landscape

Some of the leading companies in the Hypercholesterolemia pipeline drugs market are Regeneron Pharmaceuticals Inc, Verve Therapeutics Inc, Akcea Therapeutics Inc, Arrowhead Pharmaceuticals Inc, Daewoong Pharmaceutical Co Ltd, Huons Co Ltd, LipimetiX Development Inc, Novartis AG, Nyrada Inc, and Addpharma Inc.

Hypercholesterolemia Pipeline Drugs Market Analysis, by Companies

Hypercholesterolemia Pipeline Drugs Market Analysis, by Companies

To know more about the companies in the Hypercholesterolemia pipeline drugs market, download a free report sample

Hypercholesterolemia Pipeline Drugs Market Report Overview

Key Targets Proprotein Convertase Subtilisin/Kexin Type 9, 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase, Angiopoietin Related Protein 3, Apolipoprotein C III, Niemann Pick C1 Like Protein 1, Low Density Lipoprotein Receptor, Angiopoietin Related Protein 4, ATP Citrate Synthase (ATP Citrate, Cholesteryl Ester Transfer Protein, and Squalene Synthase
Key Mechanisms of Action Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor, 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase Inhibitor, Angiopoietin Related Protein 3 Inhibitor, Apolipoprotein C III Inhibitor, Niemann Pick C1 Like Protein 1 Inhibitor, Low Density Lipoprotein Receptor Agonist, Angiopoietin Related Protein 4 Inhibitor, ATP Citrate Synthase (ATP Citrate Inhibitor, Cholesteryl Ester Transfer Protein Inhibitor, and Squalene Synthase Inhibitor
Key Routes of Administration Oral, Subcutaneous, Intravenous, Buccal, Intramuscular, Intraperitoneal, Nasal, Sublingual, Topical, and Transdermal
Key Molecule Types Small Molecule, Monoclonal Antibody, Gene Therapy, Antisense Oligonucleotide, Antisense RNAi Oligonucleotide, Synthetic Peptide, Peptide, Biologic, Conjugate Vaccine, Fusion Protein, Polymer, and Subunit Vaccine
Leading Companies Regeneron Pharmaceuticals Inc, Verve Therapeutics Inc, Akcea Therapeutics Inc, Arrowhead Pharmaceuticals Inc, Daewoong Pharmaceutical Co Ltd, Huons Co Ltd, LipimetiX Development Inc, Novartis AG, Nyrada Inc, and Addpharma Inc

Scope

This report provides:

  • A snapshot of the global therapeutic landscape of Hypercholesterolemia (Metabolic Disorders).
  • Reviews of pipeline therapeutics for Hypercholesterolemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • Reviews of key companies involved in Hypercholesterolemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • Evaluation of Hypercholesterolemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news related to pipeline therapeutics for Hypercholesterolemia (Metabolic Disorders).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Hypercholesterolemia (Metabolic Disorders).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Hypercholesterolemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

3SBio Inc
Addpharma Inc
AFFiRiS AG
Akcea Therapeutics Inc
Akeso Inc
Alexion Pharmaceuticals Inc
Amgen Inc
Amryt Pharma Plc
Amytrx Therapeutics Inc
Arrowhead Pharmaceuticals Inc
Astellas Pharma Inc
AstraZeneca Plc
Beijing Mabworks Biotech Co Ltd
BioLingus AG
Bo Jiyuan (Chongqing) Pharmaceutical Technology Co Ltd
Boryung Pharmaceutical Co Ltd
CardioPharma Inc
Centeer BioTherapeutics Ltd Co
Chong Kun Dang Pharmaceutical Corporation
Civi Biopharma Inc
Daewon Pharmaceutical Co Ltd
Daewoong Pharmaceutical Co Ltd
Delivra Corp
Draupnir Bio Aps
Eight Plus One Pharmaceutical Co Ltd
Epicrispr Biotechnologies Inc
Esperion Therapeutics Inc
Golden Biotechnology Corp
Gruthan Bioscience LLC
Guangzhou Jiayue Pharmaceutical Technology Co Ltd
Haisco Pharmaceutical Group Co Ltd
Hanmi Pharmaceuticals Co Ltd
Hanmi Science Co Ltd
Hingez Therapeutics Inc
Huons Co Ltd
Imagine Pharma LLC
iMetabolic Biopharma Corp
Innovent Biologics Inc
Jiangsu Carephar Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Kyorin Pharmaceutical Co Ltd
Kyttaro Ltd
LIB Therapeutics LLC
Lipigon Pharmaceuticals AB
LipimetiX Development Inc
Luckwel Pharmaceuticals Inc
Luye Pharma Group Ltd
Lyndra Therapeutics Inc.
Mab-Science (Hong Kong) Co Ltd
Medlab Clinical Ltd
Merck & Co Inc
NeuroBo Pharmaceuticals Inc
NewAmsterdam Pharma BV
NorthSea Therapeutics BV
Novartis AG
Novo Nordisk AS
Nyrada Inc
OliPass Corporation
Orient Pharma Co Ltd
Precision Biosciences Inc
Progenra Inc
Regeneron Pharmaceuticals Inc
RegenxBio Inc
Repair Biotechnologies Inc
Saliogen Therapeutics Inc
Sanofi
Seed Health Inc
Shandong Boan Biotechnology Co Ltd
Shanghai Henlius Biotech Inc
Shanghai Junshi Bioscience Co Ltd
Shenzhen Salubris Pharmaceuticals Co Ltd
Shifa Biomedical Corp
Sirnaomics Ltd
Vaxxinity Inc
Verve Therapeutics Inc
Viking Therapeutics Inc
Zhejiang Teruisi Pharmaceutical Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hypercholesterolemia – Overview

Hypercholesterolemia – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Hypercholesterolemia – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hypercholesterolemia – Companies Involved in Therapeutics Development

Hypercholesterolemia – Drug Profiles

Hypercholesterolemia – Dormant Projects

Hypercholesterolemia – Discontinued Products

Hypercholesterolemia – Product Development Milestones

Featured News & Press Releases

Sep 23, 2022: Ionis provides update on development program evaluating PCSK9 antisense medicine for the treatment of hypercholesterolemia

Sep 21, 2022: Verve Therapeutics announces clearance of clinical trial authorisation application by the United Kingdom Medicines and Healthcare Products Regulatory Agency for VERVE-101 in patients with heterozygous familial hypercholesterolemia

Sep 13, 2022: MediciNova receives a notice of allowance for a new patent covering MN-001 and MN-002 for the treatment of hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia in Canada

Aug 29, 2022: New Amgen data at ESC 2022 show long-term LDL-C lowering with REPATHA (evolocumab) was well-tolerated for more than 8 years

Aug 29, 2022: NewAmsterdam Pharma showcases leadership in cardiometabolic disease treatment in multiple presentations at ESC congress 2022

Aug 29, 2022: Verve Therapeutics highlights preclinical data supporting nomination of VERVE-201 ANGPTL3 product candidate at the European Society of Cardiology 2022 Congress

Aug 29, 2022: AMGEN to present new data at ESC Congress 2022 highlighting up To

8.5 years of Repatha (Evolocumab) safety and tolerability data in high-risk ASCVD patient populations

Aug 29, 2022: Latest simulation analyses from the SANTORINI registry indicates that adding bempedoic acid in the lipid lowering treatment algorithm might help more patients achieve LDL-C recommended goals

Aug 02, 2022: Vaxxinity’s anti-PCSK9 candidate demonstrates durable LDL cholesterol lowering in non-human primates

Jul 28, 2022: NewAmsterdam pharma doses first patient in phase 3 BROOKLYN clinical trial evaluating obicetrapib in patients with heterozygous familial hypercholesterolemia

Jul 12, 2022: Verve Therapeutics doses first human with an investigational in vivo base editing medicine, VERVE-101, as a potential treatment for heterozygous familial hypercholesterolemia

Jun 29, 2022: Nyrada announces update on Cholesterol-Lowering Program

Jun 13, 2022: Innovent announces the NMPA acceptance of the New Drug Application for Tafolecimab Injection (anti-PCSK-9 antibody)

May 31, 2022: First Subject dosed in Lipigon’s phase I clinical study with antisense oligonucleotide Candidate Derived from Secarna Pharmaceutical’s LNAplus(TM) Technology Platform

May 21, 2022: Evkeeza (evinacumab) phase 3 trial demonstrates 48% LDL-C reduction in children with ultra-rare form of high cholesterol

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Hypercholesterolemia, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Target, 2022 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Hypercholesterolemia – Dormant Projects, 2022

Hypercholesterolemia – Dormant Projects, 2022 (Contd..1)

Hypercholesterolemia – Dormant Projects, 2022 (Contd..2)

Hypercholesterolemia – Dormant Projects, 2022 (Contd..3)

Hypercholesterolemia – Dormant Projects, 2022 (Contd..4)

Hypercholesterolemia – Dormant Projects, 2022 (Contd..5)

Hypercholesterolemia – Discontinued Products, 2022

Hypercholesterolemia – Discontinued Products, 2022 (Contd..1)

Figures

List of Figures

Number of Products under Development for Hypercholesterolemia, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

  • What are the key targets of the Hypercholesterolemia pipeline drugs market?

    Some of the key targets of the Hypercholesterolemia pipeline drugs market are Proprotein Convertase Subtilisin/Kexin Type 9, 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase, Angiopoietin Related Protein 3, Apolipoprotein C III, Niemann Pick C1 Like Protein 1, Low Density Lipoprotein Receptor, Angiopoietin Related Protein 4, ATP Citrate Synthase (ATP Citrate, Cholesteryl Ester Transfer Protein, and Squalene Synthase.

  • What are the key mechanisms of action of the Hypercholesterolemia pipeline drugs market?

    Some of the key mechanisms of action of the Hypercholesterolemia pipeline drugs market are Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor, 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase Inhibitor, Angiopoietin Related Protein 3 Inhibitor, Apolipoprotein C III Inhibitor, Niemann Pick C1 Like Protein 1 Inhibitor, Low Density Lipoprotein Receptor Agonist, Angiopoietin Related Protein 4 Inhibitor, ATP Citrate Synthase (ATP Citrate Inhibitor, Cholesteryl Ester Transfer Protein Inhibitor, and Squalene Synthase Inhibitor.

  • What are the key routes of administration in the Hypercholesterolemia pipeline drugs market?

    Some of the key routes of administration in the Hypercholesterolemia pipeline drugs market are oral, subcutaneous, intravenous, buccal, intramuscular, intraperitoneal, nasal, sublingual, topical, and transdermal.

  • What are the key molecule types in the Hypercholesterolemia pipeline drugs market?

    The key molecule types in the Hypercholesterolemia pipeline drugs market are small molecule, monoclonal antibody, gene therapy, antisense oligonucleotide, antisense RNAi oligonucleotide, synthetic peptide, peptide, biologic, conjugate vaccine, fusion protein, polymer, and subunit vaccine.

  • Which are the leading companies in the Hypercholesterolemia pipeline drugs market?

    Some of the leading companies in the Hypercholesterolemia pipeline drugs market are Regeneron Pharmaceuticals Inc, Verve Therapeutics Inc, Akcea Therapeutics Inc, Arrowhead Pharmaceuticals Inc, Daewoong Pharmaceutical Co Ltd, Huons Co Ltd, LipimetiX Development Inc, Novartis AG, Nyrada Inc, and Addpharma Inc.

Hypercholesterolemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Hypercholesterolemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Metabolic Disorders reports
Pharmaceuticals
New
Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…
$3,495 | June 2026
Pharmaceuticals
New
IgA Nephropathy (Berger’s Disease): Market View, Current and Future Competitive…
$3,495 | June 2026
Pharmaceuticals
New
Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035
$9,995 | June 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Hypercholesterolemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Hypercholesterolemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more